The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
The company plans to open a $20 million Series C round in Q2 of this year and launch a study to support a US Food and Drug Administration submission in mid-2018.
By studying variants in PCSK9, researchers reported the therapies targeting the gene would have some of the same effects as statins.
The results of this meta-analysis by University of Cambridge-led team could have implications for LDL-C-lowering therapies.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The STARNET study found that cardiometabolic disease risk loci share cis- and trans-gene regulation.
At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
A study in NEJM found that rare, loss-of-function mutations in the asialoglycoprotein receptor gene coincide with lower non-HDL levels and decreased coronary artery disease risk.
DeCode Genetics' Kari Stefansson and his colleagues uncovered a dozen genetic variants that influence blood lipids, and explored links to coronary artery disease.
The researchers found that older people with clear arteries had noticeably higher levels of CXCL5 compared with older people with more plaque buildup.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.